What it's for (Indications)
- Letrozole is an oral non-steroidal aromatase inhibitor primarily indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women.
- Specifically, its approved uses include initial adjuvant treatment of hormone receptor-positive early breast cancer; extended adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women who have completed 5 years of adjuvant tamoxifen therapy; first-line treatment of hormone receptor-positive or hormone receptor-unknown advanced breast cancer; and treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
- Its efficacy stems from its potent ability to reduce estrogen levels, thereby depriving estrogen-dependent cancer cells of growth stimulation.
- This broad utility makes it a cornerstone in the management of specific breast cancer subtypes.
- It is crucial to confirm hormone receptor status before initiating therapy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For the treatment of early or advanced breast cancer, the recommended dosage of letrozole is 2.5 mg administered orally once daily. The tablet can be taken with or without food, but it is advised to take it at approximately the same time each day to maintain consistent drug levels. In the adjuvant setting, treatment is typically continued for 5 years, or until tumor recurrence, whichever occurs first. For extended adjuvant treatment, it is administered for an additional duration following tamoxifen therapy, often for up to 5 years. For advanced breast cancer, treatment continues until tumor progression is evident. Dose adjustments are generally not required for mild to moderate renal impairment, but caution is advised in severe renal impairment. For patients with severe hepatic impairment, a 50% dose reduction (1.25 mg daily) may be considered, as letrozole is primarily metabolized by the liver, necessitating careful monitoring in such cases. |
Safety & Warnings
Common Side Effects
- Letrozole therapy is associated with a range of side effects, largely due to its potent estrogen-depleting effects.
- Very common adverse reactions (≥10%) include hot flashes, arthralgia (joint pain), fatigue, nausea, headache, sweating (including night sweats), hypercholesterolemia, and bone pain.
- Common side effects (1-10%) may encompass peripheral edema, dizziness, constipation, diarrhea, abdominal pain, dyspepsia, vomiting, alopecia, rash, weight gain, myalgia, osteoporosis, and fractures.
- Less common but potentially serious adverse events include cardiovascular events such as ischemic cardiac events, myocardial infarction, and thromboembolic events (e.
- g.
- , stroke, pulmonary embolism, deep vein thrombosis).
- Patients may also experience vaginal bleeding, increased appetite, and palpitations.
- Due to the risk of bone mineral density loss, monitoring for osteoporosis is critical during long-term treatment.
- Patients should report any persistent or severe side effects to their healthcare provider for appropriate management and evaluation.
Serious Warnings
- Black Box Warning: Letrozole does not carry a formal FDA Black Box Warning. However, several serious warnings are crucial for patient safety and clinical management due to the profound estrogen deprivation it induces. Patients should be explicitly informed about the significantly increased risk of decreased bone mineral density, osteopenia, and osteoporosis, leading to an elevated risk of fractures. Comprehensive bone health management, including baseline and periodic bone density assessments (e.g., DEXA scans), and consideration of calcium, vitamin D supplementation, or bisphosphonate therapy, is essential for all patients, particularly those undergoing long-term treatment. Furthermore, there is an increased incidence of cardiovascular events, including ischemic cardiac events, myocardial infarction, and thromboembolic events, observed in patients treated with letrozole. Careful monitoring and management of cardiovascular risk factors are imperative. Letrozole is also unequivocally contraindicated in pregnancy due to its teratogenic potential, mandating the use of highly effective contraception for women of reproductive potential during and after treatment.
- Several critical warnings are associated with letrozole use.
- Bone health is a significant concern; profound estrogen deprivation leads to an increased risk of bone mineral density loss, osteopenia, osteoporosis, and fractures.
- Baseline and periodic bone density assessments (e.
- g.
- , DEXA scans) are highly recommended, with consideration for calcium, vitamin D supplementation, or bisphosphonate therapy.
- An elevated risk of cardiovascular events, including ischemic cardiac events, myocardial infarction, and thromboembolic events, has been observed, particularly when compared to tamoxifen; therefore, patients with pre-existing cardiovascular risk factors require vigilant monitoring.
- Letrozole can also cause hypercholesterolemia, necessitating regular lipid profile monitoring.
- Due to potential fatigue, dizziness, or somnolence, patients should be cautioned about operating machinery or driving.
- Letrozole is contraindicated in pregnancy (Pregnancy Category X) due to teratogenicity and should not be used by women who are pregnant or may become pregnant; effective contraception is mandatory for women of childbearing potential.
- Caution and potential dose adjustment are warranted in patients with severe hepatic impairment.
How it Works (Mechanism of Action)
Letrozole is a highly selective, non-steroidal competitive inhibitor of the aromatase enzyme system. In postmenopausal women, the primary source of circulating estrogens (estrone and estradiol) is the peripheral conversion of adrenal androgens (androstenedione and testosterone) into estrogens, a process catalyzed by the aromatase enzyme, which is a cytochrome P450 enzyme. Letrozole works by reversibly binding to the heme component of the aromatase enzyme, thereby preventing the conversion of androgens into estrogens. This potent inhibition leads to a significant and sustained reduction in circulating estrogen levels (typically by greater than 90% in postmenopausal women) to undetectable levels. By depriving estrogen-dependent breast cancer cells of the estrogen necessary for their growth and proliferation, letrozole effectively inhibits tumor progression in hormone receptor-positive breast cancer. Its specificity for aromatase contributes to a favorable side effect profile compared to older, less selective endocrine therapies.